Duverger-van Bogaert M, Vanparys P, de Meester C, Marsboom R
Laboratory of Toxicology, UCL 7237, School of Pharmacy, Brussels, Belgium.
Drug Chem Toxicol. 1987;10(3-4):329-38. doi: 10.3109/01480548709042990.
Azaperone was evaluated for its mutagenic potential by the Salmonella/microsome test. No mutagenic activity towards six S. typhimurium strains could be evidenced with azaperone at doses up to 2,000 micrograms/plate, either without or with metabolic activation at usual test conditions. Higher concentrations of liver post-mitochondrial fraction from Aroclor 1254 (ARO)-pretreated rats did not reveal any increase in the number of revertants towards S. typhimurium strains TA1537, TA1538 and TA98. Moreover, a plate-incorporation test with liver post-mitochondrial fractions from mice pretreated with phenobarbital (PB) and a liquid preincubation test with liver post-mitochondrial fractions from rats pretreated with ARO also failed to reveal any mutagenic action of azaperone towards S. typhimurium strain TA98. Thus, none of the tests used provided any indication of azaperone having a mutagenic action.
通过沙门氏菌/微粒体试验评估了阿扎哌隆的致突变潜力。在常规试验条件下,无论有无代谢活化,剂量高达2000微克/平板的阿扎哌隆对六种鼠伤寒沙门氏菌菌株均未显示出致突变活性。来自经Aroclor 1254(ARO)预处理大鼠的肝线粒体后组分的更高浓度,未显示对鼠伤寒沙门氏菌菌株TA1537、TA1538和TA98的回复突变体数量有任何增加。此外,用苯巴比妥(PB)预处理小鼠的肝线粒体后组分进行的平板掺入试验以及用ARO预处理大鼠的肝线粒体后组分进行的液体预孵育试验,也均未显示阿扎哌隆对鼠伤寒沙门氏菌菌株TA98有任何致突变作用。因此,所使用的任何试验均未提供阿扎哌隆具有致突变作用的任何迹象。